Answers are grounded in this paper and cite their sources.
Chronic spontaneous urticaria (CSU) is an inflammatory skin condition lasting more than six weeks, characterized by itchy wheals and/or angioedema. Mast cells and basophils play a central role in the pathogenesis of CSU and their activation leads to the release of histamine and cytokines, causing dermal inflammation. Two overlapping mechanisms have been proposed for the activation of these cells in CSU: type I autoimmunity (autoallergy), mediated by IgE against various autoallergens, and type IIb autoimmunity, predominantly mediated by IgG directed against the IgE receptor FcεRI or FcεRI-bound IgE. A cornerstone of FcεRI and B-cell receptor signaling is Bruton’s tyrosine kinase (BTK). The clinical application of BTK inhibitors for B-cell malignancies has proven successful, and there is strong rationale for their potential benefits in chronic spontaneous urticaria. Recent studies on next-generation BTK inhibitors remibrutinib and fenebrutinib indicate that they could overcome some of the limitations of monoclonal antibody treatments. These inhibitors offer the hope of an effective and well-tolerated therapeutic option for patients suffering from CSU, promising symptoms’ relief and improved quality of life for those affected.
No takes yet. Share an insight, caveat, or question.
Pop et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: